SCM
FATE icon

Sterling Capital Management’s Fate Therapeutics FATE Stock Holding History

Sterling Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,600
Closed -$4.32K – 3325
2026
Q1 		$4.32K Sell
3,600
-2,668
-43% -$3.25K ﹤0.01% 2793
2025
Q4 		$6.16K Sell
6,268
-1,236
-16% -$1.48K ﹤0.01% 2819
2025
Q3 		$9.46K Buy
7,504
+4,676
+165% +$5.04K ﹤0.01% 2509
2025
Q2 		$3.17K Buy
2,828
+1,029
+57% +$1.2K ﹤0.01% 2758
2025
Q1 		$1.42K Sell
1,799
-1,601
-47% -$1.96K ﹤0.01% 2697
2024
Q4 		$5.61K Buy
3,400
+3,048
+866% +$7.68K ﹤0.01% 2420
2024
Q3 		$1.23K Buy
+352
New +$1.37K ﹤0.01% 2425
2015
Q4 		– Sell
-29,823
Closed -$159K – 998
2015
Q3 		$159K Sell
29,823
-10,897
-27% -$74.4K ﹤0.01% 929
2015
Q2 		$263K Buy
+40,720
New +$244K ﹤0.01% 817

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sterling Capital Management's FATE Position: Q2 2026 in Review

Sterling Capital Management sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 3,600 shares — an estimated $4.32K sold.

Sterling Capital Management first reported a position in FATE in Q2 2015 and held it in 9 quarters. The position peaked at $263K in Q2 2015. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Sterling Capital Management reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 3,600 Fate Therapeutics shares in Q2 2026, an estimated $4.32K.
  • Sterling Capital Management first reported a position in Fate Therapeutics in Q2 2015 and held it in 9 quarters.
  • Sterling Capital Management's Fate Therapeutics position peaked at $263K in Q2 2015.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.